Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future ...

The San Carlos, California-based biotech is now looking to use its series C cash to fund a phase 2b study to further demonstrate the efficacy of its mannose-1-phosphate replacement therapy GLM101.